2023 Was a troublesome year for your biopharma sector, with numerous companies downsizing and restructuring their workforces to remain afloat. There are actually indications of recovery, as mergers and acquisitions picked up through the pharmaceutical and lifestyle sciences market while in the latter Section of 2023 and have continued their https://sites.google.com/view/bio-sites/blog